|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2001-9-11
|
|
pubmed:abstractText |
In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11%) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9%). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48% for response and 28% for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95% confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1522-8517
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
1
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
282-8
|
|
pubmed:dateRevised |
2008-11-20
|
|
pubmed:meshHeading |
pubmed-meshheading:11550320-Actuarial Analysis,
pubmed-meshheading:11550320-Adolescent,
pubmed-meshheading:11550320-Adult,
pubmed-meshheading:11550320-Aged,
pubmed-meshheading:11550320-Aged, 80 and over,
pubmed-meshheading:11550320-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11550320-Astrocytoma,
pubmed-meshheading:11550320-Brain Neoplasms,
pubmed-meshheading:11550320-Carboplatin,
pubmed-meshheading:11550320-Combined Modality Therapy,
pubmed-meshheading:11550320-Disease Progression,
pubmed-meshheading:11550320-Disease-Free Survival,
pubmed-meshheading:11550320-Eflornithine,
pubmed-meshheading:11550320-Female,
pubmed-meshheading:11550320-Fluorouracil,
pubmed-meshheading:11550320-Glioblastoma,
pubmed-meshheading:11550320-Glioma,
pubmed-meshheading:11550320-Humans,
pubmed-meshheading:11550320-Interferon-beta,
pubmed-meshheading:11550320-Male,
pubmed-meshheading:11550320-Menogaril,
pubmed-meshheading:11550320-Middle Aged,
pubmed-meshheading:11550320-Neoplasm Recurrence, Local,
pubmed-meshheading:11550320-Procarbazine,
pubmed-meshheading:11550320-Prognosis,
pubmed-meshheading:11550320-Proportional Hazards Models,
pubmed-meshheading:11550320-Texas,
pubmed-meshheading:11550320-Treatment Outcome,
pubmed-meshheading:11550320-Tretinoin
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Response and progression in recurrent malignant glioma.
|
|
pubmed:affiliation |
Department of Biomathematics, Box 237, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study,
Clinical Trial, Phase II
|
